MasTec Inc vs uniQure N.V. Ordinary Shares — how do they compare? MasTec Inc trades at $191.47 (market cap $16.55B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: MasTec Inc is far larger — about 11.2× uniQure N.V. Ordinary Shares's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MasTec Inc for 25 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| MTZ | QURE | |
|---|---|---|
Market Cap | $16.55B | $1.48B |
Volume | 1,530,865 | 2,488,780 |
Sector | Industrials | Health |
52-Week High | $437.51 | $70.59 |
52-Week Low | $190.08 | $9.03 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $19.47B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $206.12, down 0.35% on the day, with technical indicators showing bearish momentum below key moving averages. The company reported strong revenue growth from $14.3B in 2025 to $16.1B in 2026, with net income improving to $494M. Recent news highlights MTZ's record $21.4B backlog and positioning in AI infrastructure and power delivery markets, though cash flow volatility and premium valuation pose challenges.
Wall Street maintains strong bullish sentiment with 89% buy ratings and a $403.92 consensus price target, representing 96% upside potential. Key opportunities include infrastructure investment cycles and data center expansion, while risks include execution challenges, communications segment softness, and elevated P/E ratio of 32.8x.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →